MDS AML MATTER Program

Patient Evaluation and Management Simulator Virtual Tumor Board

Access Courses

Description

Two learning opportunities provide guidance to the interdisciplinary MDS/AML care team on diagnosis and classification of MDS and AML, risk stratification and individualized treatment selection, assessment of treatment responses, and mitigation of adverse events.

Experience a new way of learning through virtual simulation activities to manage patients with MDS or AML. Each activity requires the participant to work through a case by obtaining a patient history, considering differential diagnoses, ordering and interpreting laboratory tests, and more.

In a virtual tumor board session, hear from some of your colleagues on why they chose the responses they did based on a live MDS+AML MATTER Summit session. You will be given the opportunity to answer questions in real time and hear rationale from the experts.

MDS+AML MATTER activities were created as a partnership between the American Society of Hematology (ASH), American Society for Clinical Pathology, National Marrow Donor Program/Be The Match, Oncology Nursing Society (ONS), and The France Foundation.

Target Audience

The entire interdisciplinary cancer care team involved in the diagnosis and management of patients with MDS and AML, including Hematologists, Oncologists, Hematopathologists, Pathologists, Physician Assistants, Advanced Practice Nurses, Nurses, Hematopoietic cell transplantation clinicians, and other health care professionals.

Program Goals

Provide guidance on:

  • The optimal diagnosis and classification of both MDS and AML
  • Risk stratification and individualized treatment selection
  • Assessment of treatment responses
  • Monitoring for and mitigation of adverse events, and
  • Patient education regarding prognosis and treatment choices

Faculty

Jessica Altman, MD, Chair, Northwestern University Feinberg School of Medicine, Chicago, IL
Heidi Klepin, MD, Wake Forest Baptist Health, Winston Salem, NC
AnneMarie Block, PhD, Roswell Park Cancer Institute, Buffalo, NY
Linda J. Burns, MD, Minneapolis, MN
Michael Linden, MD, PhD, University of Minnesota, Minneapolis, MN
Robert Paul Hasserjian, MD, Harvard Medical School, Boston, MA
Kirsten Roblee, BSN, RN, OCN, The James Cancer Hospital and Solove Research Institute, Columbus, OH
B. Douglas Smith, MD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Credits

ASH is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education and maintenance of certification for physicians. For questions about credit, please contact the ASH Education Department at cme@hematology.org or call toll-free 866-828-1231.
ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.
View the course descriptions for additional credit information. 
These activities are supported by an independent medical education grant from Celgene.

Questions

If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email nmdpeducation@nmdp.org.